Neurotech International Ltd. · ASX:NTI
Neurotech International — ShareCafe Small Cap "Hidden Gems" Webinar (June 2022)
17 slides from Neurotech International's conference presentation, Jun 3, 2022
Slide 1: Investor Webinar Presentation (ASX Announcement)
ASX Announcement 3 June 2022 INVESTOR WEBINAR PRESENTATION For personal use only Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company") is pleased to announce its participation in the ShareCafe Small Cap "Hidden Gems" Webinar, to be held Friday 3rd of June 2022 from 12:30pm AEST /
Slide 2: Improving Lives - Investor Presentation
For personal use only Improving Lives Investor Presentation Dr Alexandra Andrews PhD Neuroscience, BBMed Sci (Hons1st) June 2022 Chief Executive Officer
Slide 3: Disclaimer
Disclaimer For personal use only IMPORTANT INFORMATION Purpose of presentation: This presentation (including this document, any related video or oral These events are, as at the date of this presentation, expected to take place, but there cannot be any presentation, any question and answer session a
Slide 4: Neurotech is a biopharmaceutical company
Neurotech is a biopharmaceutical company focused on the development & For personal use only commercialisation of neurological solutions that improve quality of life. Exclusive worldwide Extensive preclinical World’s first whole licence studies completed plant extract cannabis clinical study Potentia
Slide 5: Capital Structure
Capital Structure For personal use only $0.060 ~$41M ~$2.33M Share price Market Cash at bank* (as at 1st June 2022) capitalisation 696M 128M^ Share on issue Options/rights 1. *as at COB 31 March 2022 4 2. ^Options are comprised at various strike prices between $0.005 to $0.09 as at 31 December 2021
Slide 6: Highly Experienced Executive Team and Board
Highly Experienced Executive Team and Board For personal use only Dr Alexandra Andrews Brian Leedman Krista Bates Prof. Allan Cripps AO Mark Davies Winton Willesse CEO Chairman Non-Executive Director Non-Executive Director Non-Executive Director Non-Executive Director Expertise in corporate More tha
Slide 7: What makes NTI164 different?
What makes NTI164 different? For personal use only CBD/THC VS NTI164 CBDA ✓ High CBDA Rare Cannabiniods ✓ Rarer Cannabinoids: CBC, CBDP, CBDB, CBN, CBG Full Plant Extract ✓ Naturally <0.3% THC Entourage Effect ✓ >4% Terpenes Patent protected ✓ Entourage Effect composition ✓ Patent pending
Slide 8: Preclinical evidence from NTI164
Preclinical evidence from NTI164 For personal use only Preclinical studies demonstrated: • Reduction in brain cell inflammation (up to 60%) • Increase in overall brain cell health and viability (in the absence of toxic insult up to 80%) • Increase in mitochondrial viability and output (in the presen
Slide 9: Why target Autism Spectrum Disorders (ASD)?
Why target Autism Spectrum Disorders (ASD)? For personal use only PREVALENCE OF A SD RISPERIDONE TREATMENT ~1 in 70 people in US$5.6b3 MARKET SIZE Australia1 US$1.85b5 US ANNUAL SALES ~1 in 44 children US$2.1b4 Since 2017, studies with medicinal cannabis (CBD + THC) have shown in the US2 Ritalin and
Slide 10: Phase I/II program detail
Phase I/II program detail For personal use only NTI64 First in human Phase I/II ASD paediatric study (S8) Commenced in May 2021 at Monash Children’s Hospital led by A/Prof. Michael Fahey • Open label – single group • 20 patients from 8 to 17yo • Dose ranging assessments (5, 10, 15 and 20 mg/kg) • In
Slide 11: Current and Future Opportunities for NTI164
Current and Future Opportunities for NTI164 For personal use only CEREBRAL MIGRAINE PALSY COMBINATION THERAPIES AUTISM US$4.4b 3 US$1.7b 5 Prednisone SPECTRUM by 2030 Future Target Diclofenac Future Target & other DISORDER TRAUMATIC US$2.3b 1 MULTIPLE SCLEROSIS ADHD BRAIN Phase I/II to INJURY comple
Slide 12: Strong Patent Position
Strong Patent Position For personal use only Neurotech has lodged two Composition strategic provisional patent applications with IP Australia Uniqueness of the NTI-164 strain – composition profile with low THC (<0.3%) to underpin future worldwide and a unique combination of ‘rarer’ commercialisation
Slide 13: Pathways to Commercialisation
Pathways to Commercialisation For personal use only The anti-inflammatory properties NTI strains in combination with minimal presence of THC (< 0.3%) provides clear pathways to commercialisation: Pharmaceutical Combination • FDA new drug registration • Fast route to commercialisation via • Huge pote
Slide 14: Neurotech vs Peers
Neurotech vs Peers For personal use only Zelira Neurotech Little Green Incannex Emyria Ltd Therapeutics Ltd International Ltd Pharma Ltd Healthcare Ltd Ticker ZLD NTI EMD LGP IHL Market Cap A$12M A$41M A$76M A$88M A$518M CBD-A, CBG, CBN, Properties CBD, CBD+THC CBN-B, CBD-P Low and High dose CBD CBD
Slide 15: NTI164 Development Program Timeline
NTI164 Development Program Timeline For personal use only Commence Phase II/III Registration Study Licensing & (Monash Children’s Commercialisation US based Hospital Department of Discussions Phase II/III study efficacy study Neurology) completion Q3 2022 Q4 Q1 2023 Q2 Q3 Q4 Pre- IND US FDA Drug Mas
Slide 16: Why Invest
Why Invest For personal use only Experienced Unique Clinical Significant board and biopharmaceutical programs near term management cannabinoid underway milestones platform targeting pivotal, & newsflow unmet needs 16
Slide 17: Contact Details
For personal use only Contact Details Dr Alexandra Andrews Media: Amalie Schreurs CEO White Noise Communications aa@neurotechinternational.com amalie@whitenoisecomms.com +61 405 339 788 +61 (0)431 636 033 www.neurotechinternational.com www.mentetech.com Neurotech International Limited (ASX: NTI) 17
Neurotech International — ShareCafe Small Cap "Hidden Gems" Webinar (June 2022) on 6ix